PapersPMID:39313030
The effects of chicory inulin-type fructans supplementation on weight management outcomes: systematic review, meta-analysis, and meta-regression of randomized controlled trials.
- findings
- 3
- compound
- 1
- endpoints
- 3
- Study, every finding
- meta-analysis
- Dose studied, every finding
- Pooled; overall median dose 10 g/d (range 3-30 g/d), median duration 12 wk (range 4-36 wk)
What moved
How to read these marks →- Decreases fat mass
moderate
“The pooled estimate from the random-effects model showed that ITF supplementation significantly reduced total fat mass (MD: −0.37 kg; 95% CI: −0.61, −0.13; P = 0.01; I2: 0%), compared with placebo.”
- Effect
- −0.37 mean difference, 95% CI −0.61 to −0.13
- Population
- Adults in randomized controlled trials of chicory inulin-type fructans versus placebo or control; pooled analysis of 9 trials
- Decreases body mass index
moderate
“As depicted in Figure 3, the pooled estimate from the random-effects model showed that a reduction in BMI (MD: −0.39 kg/m2; 95% CI: −0.57, −0.20; P = 0.0002) following chicory ITF supplementation was evident from 25 trials (available as 28 reports, n = 985 subjects).”
- Participants
- 985
- Effect
- −0.39 mean difference, 95% CI −0.57 to −0.2
- Population
- Adults in randomized controlled trials of chicory inulin-type fructans versus placebo or control; pooled analysis of 25 trials
- Decreases waist circumference
moderate
“The overall pooled estimate of waist circumference from the random-effects model showed a significant reduction (MD: −1.03 cm; 95% CI: −1.69, −0.37; P = 0.004, I2: 51%) following ITF supplementation, compared with control.”
- Effect
- −1.03 mean difference, 95% CI −1.69 to −0.37
- Population
- Adults in randomized controlled trials of chicory inulin-type fructans versus placebo or control; pooled analysis of 14 trials
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Adults in 32 RCTs of chicory inulin-type fructans (inulin, oligofructose, oligofructose-enriched inulin) versus placebo/control: overweight/obesity, T2D, prediabetes, healthy, NAFLD, NASH and other conditions
- Participants
- 1,184
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 49